特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
769552

腎癌治療薬市場 - 市場規模、シェア、見通し、市場機会の分析 2018年~2026年

Kidney Cancer Drugs Market - Size, Share, Outlook, and Opportunity Analysis, 2018-2026

出版日: | 発行: Coherent Market Insights | ページ情報: 英文 173 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=104.83円
腎癌治療薬市場 - 市場規模、シェア、見通し、市場機会の分析 2018年~2026年
出版日: 2018年12月28日
発行: Coherent Market Insights
ページ情報: 英文 173 Pages
納期: 2-3営業日
  • 全表示
  • 概要
  • 目次
概要

腎細胞癌は成人の腎癌で最も一般的なもののひとつです。癌細胞の除去が不可欠である進行期腎癌では、治療のために腎臓の外科的切除が行われます。この治療法はのちに腹腔鏡下手術によって行われるようになりました。肝癌治療薬は主に進行段階の癌腫瘍を治療するために処方されます。

当レポートでは、腎癌治療薬の世界市場を調査し、市場の概要、治療法・薬理学クラス・流通チャネル・地域別の市場規模の推移と予測、市場の成長要因および阻害要因の分析、市場機会、競合情勢、主要企業のプロファイルなど、包括的な情報を提供しています。

目次

第1章 調査目的と前提条件

  • 調査目的
  • 前提条件
  • 略語

第2章 市場の概要

  • レポートの説明
    • 市場の定義と範囲
  • エグゼクティブサマリー
    • 市場スニペット:治療法別
    • 市場スニペット:薬理学クラス別
    • 市場スニペット:流通チャネル別
    • 市場スニペット:地域別
  • コヒーレントオポチュニティマップ(COM)

第3章 市場力学、規制、動向分析

  • 市場力学
    • 市場動向
    • 阻害要因
    • 市場機会
  • 影響分析
  • 市場動向
  • 疫学
  • 主な開発
  • 戦略的コラボレーションと買収
  • 規制シナリオ
  • 償還制度の分析
  • パイプライン分析

第4章 世界の腎癌治療薬市場:治療法別

  • イントロダクション
  • 標的療法
  • 免疫療法
  • 化学療法

第5章 世界の腎癌治療薬市場:薬理学クラス別

  • イントロダクション
  • 血管新生阻害剤
  • mTOR阻害剤
  • サイトカイン
  • その他(免疫チェックポイント阻害薬、CTLA-4阻害薬、代謝拮抗薬など)

第6章 世界の腎癌治療薬市場:流通経路別

  • イントロダクション
  • 病院薬局
  • 小売薬局
  • オンライン薬局

第7章 世界の腎癌治療薬市場:地域別

  • イントロダクション
  • 北米
  • 欧州
  • アジア太平洋地域
  • ラテンアメリカ
  • アフリカ
  • 中東

第8章 競争環境

  • ヒートマップ解析
  • 企業プロファイル
    • Pfizer Inc.
    • Novartis International AG
    • Genentech, Inc.
    • Active Biotech AB
    • Amgen Inc.
    • Bayer AG
    • Cipla Limited
    • Hoffmann-La Roche AG
    • Bristol-Myers Squibb Company
    • エーザイ
    • Exelixis, Inc.

第9章 セクション

目次
  • Renal cell carcinoma (RCC) is one of the most common types of kidney cancer in adults. At the advanced progression stage of kidney cancer, where removal of the cancerous cells is vital; surgical removal of kidney are performed to get cure from the disease. This treatment method was later replaced by laparoscopic removal of tumor-affected area. Medicines are generally prescribed to cure tumors at advanced stage of disease progression.
  • In recent times, owing to increasing drug resistivity key players are shifting its focus in developing combination drug therapy for kidney cancer medication. Increasing trend of combination drug therapy in near future, will help in overcoming potential hazards of drug resistivity and offer treatment option in renal cell carcinoma.
  • In addition, key players are engaged in developing cancer immunotherapy drugs to fight cancer and improve immune system. For instance, F. Hoffmann-La Roche Ltd. Is working on Tecentriq (atezolizumab, anti-PDL1, RG7446, MPDL3280A) - an engineered monoclonal antibody, that targets the ligand PD-L1 (programmed death ligand 1) aiming to prevent cancer immune evasion- which will be used as adjuvant treatment in renal cell carcinoma treatment. Tecentriq is currently in phase III stage, which is expected to be launched in the market by the end of 2021.

Market Dynamics

  • Key drug manufacturers in the kidney cancer drugs market are adopting in-organic growth strategies to collaborate with other drug manufacturers and develop renal cell carcinoma drugs.
  • For instance, in March 2018, Eisai Co., Ltd. And Merck & Co., Inc. entered into strategic collaboration agreement for co-development and co-commercialization of LENVIMA (lenvatinib mesylate), an orally available tyrosine kinase inhibitor, for renal cell carcinoma. Under the terms of agreement, Eisai and Merck will develop and commercialize LENVIMA jointly, both as monotherapy and in combination with Merck's anti-PD-1 therapy, KEYTRUDA (pembrolizumab).
  • Moreover, in June 2016, Eisai Co., Ltd. Entered into a partnership with Novartis Pharmaceuticals to collaborate on commercial and medical affairs activities on a combination treatment for advanced renal cell carcinoma. According to the agreement, sales teams from both pharmaceutical companies will promote the availability of Levinima (lenvatinib mesylate) to healthcare professionals in the U.S.
  • In December 2013, Cancer Research UK and Cancer Research Technology, signed an agreement with AstraZeneca to take AZD2098, an experimental drug originally designed for asthma, into a clinical trial to treat kidney cancer.

Key features of the study:

  • This report provides in-depth analysis of kidney cancer drugs market, its market size (US$ Million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2018 - 2026), considering 2018, as the base year.
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, regional outlook, and competitive strategy adopted by key players
  • It profiles key players in the global kidney cancer drugs market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies.
  • Key companies covered as a part of this study include, Pfizer Inc., Novartis International AG, Genentech, Inc., Active Biotech AB, Amgen Inc., Bayer AG, Cipla Limited, Hoffmann-La Roche AG, Bristol-Myers Squibb Company, Eisai Co., Ltd. And Exelixis, Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future type upgradation, market expansion, and marketing tactics
  • The global kidney cancer drugs market report caters to various stakeholders in this industry including investors, researchers, kidney cancer drug manufacturers, new entrants, and financial analysts.
  • Stakeholders would have ease in decision making through the various strategy matrices used in analyzing the kidney cancer drugs market.

Detailed Segmentation:

  • Global Kidney Cancer Drugs Market, By Therapy:
  • Targeted Therapy
  • Immunotherapy
  • Chemotherapy
  • Global Kidney Cancer Drugs Market, By Pharmacological Class:
  • Angiogenesis Inhibitors
  • mTOR Inhibitors
  • Cytokines
  • Others (Immune checkpoint inhibitors, CTLA-4 inhibitors, antimetabolites and others)
  • Global Kidney Cancer Drugs Market, By Distribution Channel:
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Global Kidney Cancer Drugs Market, By Geography:
  • North America
    • By Country:
  • U.S.
  • Canada
    • By Therapy:
  • Targeted Therapy
  • Immunotherapy
  • Chemotherapy
    • By Pharmacological Class:
  • Angiogenesis Inhibitors
  • mTOR Inhibitors
  • Cytokines
  • Others (Immune checkpoint inhibitors, CTLA-4 inhibitors, antimetabolites and others)
    • By Distribution Channel:
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Europe
    • By Country:
  • U.K.
  • Germany
  • Italy
  • Spain
  • France
  • Russia
  • Rest of Europe
    • By Therapy:
  • Targeted Therapy
  • Immunotherapy
  • Chemotherapy
    • By Pharmacological Class:
  • Angiogenesis Inhibitors
  • mTOR Inhibitors
  • Cytokines
  • Others (Immune checkpoint inhibitors, CTLA-4 inhibitors, antimetabolites and others)
    • By Distribution Channel:
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Asia Pacific
    • By Country:
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
    • By Therapy:
  • Targeted Therapy
  • Immunotherapy
  • Chemotherapy
    • By Pharmacological Class:
  • Angiogenesis Inhibitors
  • mTOR Inhibitors
  • Cytokines
  • Others (Immune checkpoint inhibitors, CTLA-4 inhibitors, antimetabolites and others)
    • By Distribution Channel:
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Latin America
    • By Country:
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
    • By Therapy:
  • Targeted Therapy
  • Immunotherapy
  • Chemotherapy
    • By Pharmacological Class:
  • Angiogenesis Inhibitors
  • mTOR Inhibitors
  • Cytokines
  • Others (Immune checkpoint inhibitors, CTLA-4 inhibitors, antimetabolites and others)
    • By Distribution Channel:
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Middle East
    • By Country:
  • GCC
  • Israel
  • Rest of Middle East
    • By Therapy:
  • Targeted Therapy
  • Immunotherapy
  • Chemotherapy
    • By Pharmacological Class:
  • Angiogenesis Inhibitors
  • mTOR Inhibitors
  • Cytokines
  • Others (Immune checkpoint inhibitors, CTLA-4 inhibitors, antimetabolites and others)
    • By Distribution Channel:
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Africa
    • By Country:
  • North Africa
  • Central Africa
  • South Africa
    • By Therapy:
  • Targeted Therapy
  • Immunotherapy
  • Chemotherapy
    • By Pharmacological Class:
  • Angiogenesis Inhibitors
  • mTOR Inhibitors
  • Cytokines
  • Others (Immune checkpoint inhibitors, CTLA-4 inhibitors, antimetabolites and others)
    • By Distribution Channel:
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Company Profiles
  • Pfizer Inc.*
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Key Strategies
    • Recent Developments
  • Novartis International AG
  • Genentech, Inc.
  • Active Biotech AB
  • Amgen Inc.
  • Bayer AG
  • Cipla Limited
  • Hoffmann-La Roche AG
  • Bristol-Myers Squibb Company
  • Eisai Co., Ltd.
  • Exelixis, Inc.

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objective and Assumption

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Overview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Therapy
    • Market Snippet, By Pharmacologic Class
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Market Trends
  • Epidemiology
  • Key Developments
  • Strategic Collaborations & Acquisitions
  • Regulatory Scenario
  • Reimbursement Analysis
  • Pipeline Analysis

4. Global Kidney Cancer Drugs Market, By Therapy, 2018 - 2026, (US$ Million)

  • Introduction
    • Market Share Analysis, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, 2017 - 2026
    • Segment Trends
  • Targeted Therapy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
  • Immunotherapy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
  • Chemotherapy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)

5. Global Kidney Cancer Drugs Market, By Pharmacologic Class, 2018 - 2026, (US$ Million)

  • Introduction
    • Market Share Analysis, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, 2017 - 2026
    • Segment Trends
  • Angiogenesis Inhibitors
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
  • mTOR Inhibitors
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
  • Cytokines
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
  • Others (Immune checkpoint inhibitors, CTLA-4 inhibitors, antimetabolites and others)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)

6. Global Kidney Cancer Drugs Market, By Distribution Channel, 2018 - 2026, (US$ Million)

  • Introduction
    • Market Share Analysis, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, 2017 - 2026
    • Segment Trends
  • Hospital Pharmacy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
  • Retail Pharmacy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
  • Online Pharmacy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)

7. Global Kidney Cancer Drugs Market, By Region, 2018 - 2026, (US$ Million)

  • Introduction
    • Market Share Analysis, By Region, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, By Region, 2017 - 2026
  • North America
    • Market Size and Forecast, By Therapy, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Pharmacologic Class, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2018 - 2026, (US$ Million)
  • U.S.
  • Canada
  • Europe
    • Market Size and Forecast, By Therapy, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Pharmacologic Class, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2018 - 2026, (US$ Million)
  • U.K.
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Therapy, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Pharmacologic Class, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2018 - 2026, (US$ Million)
  • China
  • Japan
  • India
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Latin America
    • Market Size and Forecast, By Therapy, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Pharmacologic Class, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2018 - 2026, (US$ Million)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Africa
    • Market Size and Forecast, By Therapy, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Pharmacologic Class, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2018 - 2026, (US$ Million)
  • North Africa
  • Central Africa
  • South Africa
  • Middle East
    • Market Size and Forecast, By Therapy, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Pharmacologic Class, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2018 - 2026, (US$ Million)
  • GCC Countries
  • Israel
  • Rest of Middle East

8. Competitive Landscape

  • Heat Map Analysis
  • Company Profiles
    • Pfizer Inc.
  • Company Overview
  • Drug Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Key Strategies
    • Novartis International AG
  • Company Overview
  • Drug Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Key Strategies
    • Genentech, Inc.
  • Company Overview
  • Drug Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Key Strategies
    • Active Biotech AB
  • Company Overview
  • Drug Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Key Strategies
    • Amgen Inc.
  • Company Overview
  • Drug Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Key Strategies
    • Bayer AG
  • Company Overview
  • Drug Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Key Strategies
    • Cipla Limited
  • Company Overview
  • Drug Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Key Strategies
    • Hoffmann-La Roche AG
  • Company Overview
  • Drug Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Key Strategies
    • Bristol-Myers Squibb Company
  • Company Overview
  • Drug Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Key Strategies
    • Eisai Co., Ltd.
  • Company Overview
  • Drug Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Key Strategies
    • Exelixis, Inc.
  • Company Overview
  • Drug Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Key Strategies

9. Section

  • References
  • Research Methodology
  • About Us and Sales Contact
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.